Similar articles

• Phase I study of recombinant human tumor necrosis factor.

  Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, et al. Kimura K, et al. Cancer Chemother Pharmacol. 1987;20(3):223-9. doi: 10.1007/BF00570490. Cancer Chemother Pharmacol. 1987. PMID: 3315281 Clinical Trial.
• Clinical studies with tumour necrosis factor.

  Spriggs DR, Sherman ML, Frei E 3rd, Kufe DW. Spriggs DR, et al. Ciba Found Symp. 1987;131:206-27. doi: 10.1002/9780470513521.ch14. Ciba Found Symp. 1987. PMID: 3330011 Review.
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

  Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Lawrence D, et al. Nat Med. 2001 Apr;7(4):383-5. doi: 10.1038/86397. Nat Med. 2001. PMID: 11283636 No abstract available.
• Avoiding premature apoptosis of normal epidermal cells.

  Qin J, Chaturvedi V, Bonish B, Nickoloff BJ. Qin J, et al. Nat Med. 2001 Apr;7(4):385-6. doi: 10.1038/86401. Nat Med. 2001. PMID: 11283637 No abstract available.
• [Tumor necrosis factor].

  Herrmann F, Mertelsmann R. Herrmann F, et al. Dtsch Med Wochenschr. 1989 Feb 24;114(8):312-6. doi: 10.1055/s-0029-1235647. Dtsch Med Wochenschr. 1989. PMID: 2646094 Review. German. No abstract available.